Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial to Evaluate Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin Microneedle Arrays in Subjects With Basal Cell Cancer (Part II)

X
Trial Profile

A Trial to Evaluate Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin Microneedle Arrays in Subjects With Basal Cell Cancer (Part II)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors SkinJect
  • Most Recent Events

    • 11 Apr 2023 Number of arms changed from 5 to 2. Placebo Comparator: Placebo-containing MNA, Active Comparator: Doxorubicin-containing MNA - 50 µg and Active Comparator: Doxorubicin-containing MNA - 200 µg arm removed from study protocol.
    • 11 Apr 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2024.
    • 11 Apr 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Dec 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top